Genmab (Nasdaq: GMAB) AGM backs 2025 profit and trims capital
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S held its Annual General Meeting on March 19, 2026, where shareholders approved the 2025 Annual Report and gave discharge to the Board of Directors and Executive Management. The year’s profit of USD 963 million will be carried forward to retained earnings.
Six directors were re-elected for one year, and Deloitte was re-appointed as auditor. Shareholders also approved a reduction of the company’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. The proposal on 2026 Board remuneration was withdrawn, with a new proposal to be presented later.
Positive
- None.
Negative
- None.
FAQ
How did Genmab (GMAB) decide to use its 2025 profit at the AGM?
Genmab decided to carry forward the 2025 profit of USD 963 million by transferring it to retained earnings. This means the profit stays within the company’s equity rather than being distributed, supporting flexibility for future investment or other corporate purposes.
What capital reduction was approved at Genmab’s 2026 AGM?
The meeting approved a reduction of Genmab’s share capital by nominally DKK 1,900,000 through cancellation of treasury shares. This decreases the registered share capital, typically reflecting previously repurchased shares, and can marginally increase ownership percentages of remaining shareholders.
Were Genmab (GMAB) board members re-elected at the 2026 AGM?
Yes. Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Elizabeth O’Farrell, Paolo Paoletti and Anders Gersel Pedersen were all re-elected. Each will serve a one-year term, providing continuity in the company’s board-level oversight and strategic governance.
What happened to Genmab’s 2026 Board remuneration proposal?
The proposal regarding the Board of Directors’ remuneration for 2026 was withdrawn at the meeting. Management stated that a revised remuneration proposal will be presented for shareholder consideration at a later time, leaving 2026 board pay terms temporarily unresolved.
Who is Genmab’s auditor after the 2026 Annual General Meeting?
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as Genmab’s auditor. This decision maintains the existing audit relationship, meaning the same firm continues to review the company’s financial statements and provide independent assurance on reported figures.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MARCH 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated March 19, 2026: Passing of Genmab A/S’ Annual General Meeting | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: MARCH 19, 2026
Exhibit 99.1
Passing of Genmab A/S’ Annual General Meeting
Company Announcement
•At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved
•Discharge was given to the Board of Directors and the Executive Management and the year’s profit was carried forward
•The 2025 Compensation Report was approved
•Six members of the Board of Directors were re-elected
•Deloitte was re-elected as the auditor of the Company
•The proposal from the Board of Directors to reduce the Company’s share capital with nominally DKK 1,900,000 by cancellation of the Company's holding of shares was adopted
COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Deirdre P. Connelly, Chair of the Board of Directors gave – on behalf of the Board of Directors – a report on the Company’s activities during the past year. Chief Executive Officer Dr. Jan van de Winkel presented the Company’s plans for 2026, and Chief Financial Officer Mr. Anthony Pagano presented the Annual Report for 2025 endorsed by the auditors. The report was approved, and discharge was given to the Board of Directors and the Executive Management.
It was decided that the year’s profit of USD 963 million be carried forward by transfer to retained earnings, as stated in the Annual Report.
The 2025 Compensation Report was approved.
Ms. Deirdre P. Connelly, Ms. Pernille Erenbjerg, Mr. Rolf Hoffmann, Ms. Elizabeth O’Farrell, Dr. Paolo Paoletti and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period.
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.
The General Meeting adopted the proposal from the Board of Directors to reduce the Company’s share capital for the purpose of cancelling treasury shares.
The proposal from the Board of Directors on the Board of Directors’ remuneration for 2026 was withdrawn. A proposal will be put forward in due course for consideration by shareholders.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 17 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Passing of Genmab A/S’ Annual General Meeting
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 17 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||